PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2010 April; 54(4): 1650–1651.
Published online 2010 February 1. doi:  10.1128/AAC.01821-09
PMCID: PMC2849365

In Vitro Activity of Penem-1 in Combination with β-Lactams against blaKPC-Possessing Klebsiella pneumoniae Isolates[down-pointing small open triangle]

Andrea Endimiani
Department of Medicine
Case Western Reserve University School of Medicine
10900 Euclid Ave.
Cleveland, Ohio 44106

The widespread dissemination of blaKPC-possessing Klebsiella pneumoniae isolates represents a serious threat for hospitalized patients (4, 8). blaKPC-possessing K. pneumoniae isolates are resistant to all β-lactams, commercially available β-lactam-β-lactamase inhibitor combinations, quinolones, and frequently to aminoglycosides (5, 8). Furthermore, blaKPC-possessing K. pneumoniae isolates can manifest a phenotype of nonsusceptibility to tigecycline and colistin (6, 7). As a result, new therapeutic strategies against infections due to blaKPC-possessing K. pneumoniae isolates should be quickly developed.

Penem-1 (Wyeth Research) is a novel serine-reactive β-lactamase inhibitor with potent activity against class A, C, and D enzymes (1, 10). We recently demonstrated that this methylidene penem is a potent inhibitor of the KPC-2 carbapenemase (with a Km or Ki of 60 nM and a kcat/kinact of 250, where kinact is the rate constant of enzyme inactivation) (9). Data regarding the in vitro activity of penem-1 in combination with various commercially available β-lactams against blaKPC-possessing K. pneumoniae clinical isolates are not yet available.

In this work, we tested the in vitro activity of penem-1 in combination with four β-lactams against a collection of 42 previously characterized blaKPC-possessing K. pneumoniae clinical isolates that produce multiple β-lactamases (5). MICs of β-lactams and β-lactams combined with penem-1 (at a constant concentration of 4 μg/ml) were determined by the agar dilution method according to Clinical and Laboratory Standards Institute (CLSI) criteria (2) using cation-adjusted Mueller-Hinton agar (BBL; Becton Dickinson) and a Steers replicator that delivers 104 CFU/10-μl spot. Piperacillin, cefotaxime, aztreonam (Sigma Chemical Co.), and cefepime (Apotex Corp.) were combined with penem-1. The following ATCC control strains were used: Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, and K. pneumoniae ATCC 700603. MIC results, including those for the combinations with penem-1, were interpreted according to the CLSI criteria established for the β-lactams when tested alone (3).

As shown in Fig. Fig.1,1, piperacillin and aztreonam exhibited very high MICs (MIC50s, ≥512 μg/ml) when tested against blaKPC-possessing K. pneumoniae isolates whereas cefotaxime and cefepime exhibited lower MICs (MIC50s, 64 and 32 μg/ml, respectively). When penem-1 was tested alone, this inhibitor did not show activity against blaKPC-possessing K. pneumoniae strains (MICs for all strains, >128 μg/ml) (data not shown). When penem-1 was combined with piperacillin, aztreonam, or cefotaxime, the MICs remained mostly in the resistant range. In contrast, cefepime in combination with penem-1 showed significantly better results, with an overall proportion of susceptible strains of 88.1% (Fig. (Fig.11).

FIG. 1.
Distributions of MICs of piperacillin, aztreonam, cefotaxime, and cefepime and their combinations with penem-1 (Pen-1) obtained using the agar diffusion method. Results were interpreted according to CLSI criteria (3). Dashed line, susceptibility (S) cutoff. ...

In conclusion, we show here that penem-1 possesses good ability to lower the MICs of β-lactams (usually by at least three to four 2-fold dilutions from those of the β-lactam alone) when tested against blaKPC-possessing K. pneumoniae clinical isolates. This new β-lactamase inhibitor undergoes novel reaction chemistry when acylated in the active site and is superior to clavulanate and tazobactam (5, 9). The combination with cefepime represents a possible therapeutic option against infections due to blaKPC-possessing K. pneumoniae isolates. Further in vitro studies should be performed to establish the possible spectrum of application of β-lactam-penem-1 combinations against different types of multidrug-resistant Gram-negative organisms.

Acknowledgments

This work was supported by the Veterans Affairs Merit Review Program (R.A.B.), the National Institutes of Health (grant no. R03-AI081036 to R.A.B.), and the Geriatric Research Education and Clinical Center VISN 10 (R.A.B.). We thank Louis B. Rice, David L. Paterson, Michael R. Jacobs, Gerri S. Hall, and Stephen G. Jenkins for providing K. pneumoniae isolates. We also thank Tarek S. Mansour for the kind gift of penem-1.

Footnotes

[down-pointing small open triangle]Published ahead of print on 1 February 2010.

REFERENCES

1. Bethel, C. R., A. M. Distler, M. W. Ruszczycky, M. P. Carey, P. R. Carey, A. M. Hujer, M. Taracila, M. S. Helfand, J. M. Thomson, M. Kalp, V. E. Anderson, D. A. Leonard, K. M. Hujer, T. Abe, A. M. Venkatesan, T. S. Mansour, and R. A. Bonomo.2008. Inhibition of OXA-1 β-lactamase by penems. Antimicrob. Agents Chemother. 52:3135-3143. [PMC free article] [PubMed]
2. CLSI.2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
3. CLSI.2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Endimiani, A., J. M. Depasquale, S. Forero, F. Perez, A. M. Hujer, D. Roberts-Pollack, P. D. Fiorella, N. Pickens, B. Kitchel, A. E. Casiano-Colon, F. C. Tenover, and R. A. Bonomo.2009. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J. Antimicrob. Chemother. 64:1102-1110. [PMC free article] [PubMed]
5. Endimiani, A., A. M. Hujer, F. Perez, C. R. Bethel, K. M. Hujer, J. Kroeger, M. Oethinger, D. L. Paterson, M. D. Adams, M. R. Jacobs, D. J. Diekema, G. S. Hall, S. G. Jenkins, L. B. Rice, F. C. Tenover, and R. A. Bonomo.2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J. Antimicrob. Chemother. 63:427-437. [PMC free article] [PubMed]
6. Endimiani, A., G. Patel, K. M. Hujer, M. Swaminathan, F. Perez, L. B. Rice, M. R. Jacobs, and R. A. Bonomo.2010. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54:526-529. [PMC free article] [PubMed]
7. Lee, J., G. Patel, S. Huprikar, D. P. Calfee, and S. G. Jenkins.2009. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47:1611-1612. [PMC free article] [PubMed]
8. Nordmann, P., G. Cuzon, and T. Naas.2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236. [PubMed]
9. Papp-Wallace, K. M., C. R. Bethel, A. M. Distler, C. Kasuboski, M. Taracila, and R. A. Bonomo.2010. Inhibitor resistance in the KPC-2 β-lactamase: a preeminent property of this class A β-lactamase. Antimicrob. Agents Chemother. 54:890-897. [PMC free article] [PubMed]
10. Weiss, W. J., P. J. Petersen, T. M. Murphy, L. Tardio, Y. Yang, P. A. Bradford, A. M. Venkatesan, T. Abe, T. Isoda, A. Mihira, H. Ushirogochi, T. Takasake, S. Projan, J. O'Connell, and T. S. Mansour.2004. In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors. Antimicrob. Agents Chemother. 48:4589-4596. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)